Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "IFF"

1337 News Found

Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive
Healthcare | October 18, 2025

Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive

Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training


AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025
Clinical Trials | October 14, 2025

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers


Fredun Pharmaceuticals launches India's first pure Jain dog biscuit
News | October 14, 2025

Fredun Pharmaceuticals launches India's first pure Jain dog biscuit

This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem


Gilead and Kite to transform cancer care with new data at ESMO 2025
Clinical Trials | October 14, 2025

Gilead and Kite to transform cancer care with new data at ESMO 2025

The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy


Roche to present latest cancer care data at ESMO 2025
Clinical Trials | October 13, 2025

Roche to present latest cancer care data at ESMO 2025

Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant


AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025
Clinical Trials | October 13, 2025

AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


AstraZeneca to lower cost of medicines for American patients
Policy | October 12, 2025

AstraZeneca to lower cost of medicines for American patients

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing


Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
News | October 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases